Join The Discussion

 

Super PAC Men: How political consultants took a Fort Worth oilman on a wild ride

The head of a Texas oil dynasty joined the parade of wealthy political donors, aiming to flip the Senate to Republicans. By the time consultants were done with him, the war chest was drained and fraud allegations were flying

read more >

Bon Appétit: New French restaurant dishes out the finest in Fort Worth

Barely open six months, Le Cep, a contemporary French restaurant proffering fine dining, is stirring up Fort Worth’s culinary scene.

read more >

Bridge collapse on I-35 north of Austin

SALADO, Texas (AP) — Emergency crews are responding to a reported bridge collapse along an interstate in Central Texas.

read more >

Bombay Co.'s former HQ building purchased

The Bombay Co.’s former Fort Worth headquarters building has been sold, with private equity fund Diversified International Partners snapping up the seven-story, 122,828-square-foot structure at 550 Bailey St.

read more >

Latin-inspired restaurant set to open in downtown Fort Worth

Downtown Fort Worth’s dining scene is about to get spicier with the opening of a new restaurant featuring Latin-inspired coastal cuisine.

read more >

 

Galderma gains distribution rights in U.S., Canada

Nestle S.A., Switzerland, a shareholder of Fort Worth-based Galderma Laboratories LP, has entered into an agreement with Valeant Pharmaceuticals International Inc. to become the distributor of several products in aesthetic dermatology.
Galderma will gain full rights to commercialize Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the United States and Canada.
Restylane, Perlane and Emervel are manufactured by Galderma and sold by its subsidiaries globally, except in the U.S. and Canada, where Valeant holds the distribution rights under terms of a pre-existing agreement with Medicis, which was acquired by Valeant in 2012. Through this transaction, Galderma will be able to further develop and supply these brands globally.


Galderma is acquiring Sculptra, owned by Valeant, and will commercialize it in the U.S. and Canada and select other markets around the world.
Dysport (branded Azzalure in Europe) is marketed by Galderma for aesthetic dermatology indications in many markets around the world. Valeant holds the distribution rights for the aesthetic dermatology indications under a similar agreement with Ipsen. The transaction will allow Galderma to distribute Dysport in the U.S. and Canada.


“The U.S. and Canada represent more than 50 percent of the fast growing global medical aesthetics market. This move secures Galderma’s continued ability to invest in product innovation, medical education, customer service and consumer awareness,” said Humberto C. Antunes, president and chief executive officer of Galderma worldwide.
This transaction is subject to regulatory clearance and other customary closing conditions. Credit Suisse acted as financial advisers, and Debevoise and Plimpton as legal advisers to Galderma.
In February 2014, Nestle announced that it had entered into an agreement with L’Oreal S.A. under which it will acquire the remaining 50 percent of Galderma owned by L’Oreal. The transaction between Nestle and Valeant is subject to regulatory clearance and certain other conditions, and is expected to close in July.

Betty Dillard
bdillard@bizpress.net
 

< back

Email   email
hide
Catch
How 'bout them Cowboys?